Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• B7-1 (CD80) and B7-2 (CD86) are crucial co-stimulatory molecules for T-cell activation.
• Anticancer therapies can modulate the tumor microenvironment and immune cell interactions.
• Understanding how treatments affect immune-related molecules on tumor cells is vital for improving efficacy.

Purpose of the Study:

• To investigate the effect of low-dose melphalan (l -PAM) on B7-1 and B7-2 expression in MOPC-315 plasmacytoma.
• To determine if the observed effect is a direct consequence of l -PAM on tumor cells.
• To explore whether other anticancer agents share this immune-modulating property.

Main Methods:

• Administration of low-dose melphalan to mice bearing MOPC-315 tumors.
• In vitro exposure of MOPC-315 tumor cells and P815 mastocytoma cells to l -PAM, gamma-irradiation, and mitomycin C.
• Analysis of B7-1 (CD80) and B7-2 (CD86) surface expression using flow cytometry.
• Assessment of protein and RNA synthesis requirements for B7-1 up-regulation.
• Measurement of B7-1 mRNA levels.

Main Results:

• Low-dose melphalan rapidly and preferentially up-regulated B7-1 (but not B7-2) on MOPC-315 tumor cells in vivo.
• In vitro exposure to l -PAM directly induced preferential B7-1 up-regulation on MOPC-315 cells.
• Gamma-irradiation and mitomycin C also caused preferential B7-1 up-regulation on tumor cells (MOPC-315 and P815).
• The up-regulation of B7-1 required de novo protein and RNA synthesis and involved increased B7-1 mRNA levels, indicating transcriptional regulation.

Conclusions:

• Anticancer agents like l -PAM, gamma-irradiation, and mitomycin C can directly enhance tumor cell B7-1 expression.
• This preferential B7-1 up-regulation is regulated at the transcriptional level.
• These findings suggest a novel immune-potentiating mechanism for these therapies, potentially enhancing anti-tumor immune responses.